Skip to content

NBP

NovaBridge Biosciences

NASDAQ · Healthcare · Biotechnology · US

$1.62
−0.61%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
+48.6%
EBIT
+50.9%
EPS
+19.6%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS
-90.9%

Three-year CAGR

Revenue
EBITDA
+96.4%
EBIT
+96.4%
Net income
+95.9%
EPS
+96.4%
Free cash flow
+94.6%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026